Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients

Scott M. Cheney, Paul E. Andrews, Bradley C. Leibovich, Erik P Castle

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate outcomes of the first 18 patients treated with robot-assisted retroperitoneal lymph node dissection (RA-RPLND) for non-seminomatous germ cell tumours (NSGCT) and paratesticular rhabdomyosarcoma (RMS) at our institution.

PATIENTS AND METHODS: Between March 2008 and May 2013, 17 patients underwent RA-RPLND for NSGCT and one for paratesticular RMS. Data were collected retrospectively on patient demographics, preoperative tumour characteristics, and perioperative outcomes including open conversion rate, lymph node (LN) yield, rate of positive LNs, operative time, estimated blood loss (EBL), and length of stay (LOS). Perioperative outcomes were compared between patients receiving primary RA-RPLND vs post-chemotherapy RA-RPLND. Medium-term outcomes of tumour recurrence rate and maintenance of antegrade ejaculation were recorded.

RESULTS: RA-RPLND was completed robotically in 15 of 18 (83%) patients. LNs were positive in eight of 18 patients (44%). The mean LN yield was 22 LNs. For cases completed robotically, the mean operative time was 329 min, EBL was 103 mL, and LOS was 2.4 days. At a mean (range) follow-up of 22 (1-58) months, there were no retroperitoneal recurrences and two of 17 (12%) patients with NSGCT had pulmonary recurrences. Antegrade ejaculation was maintained in 91% of patients with a nerve-sparing approach. Patients receiving primary RA-RPLND had shorter operative times compared with those post-chemotherapy (311 vs 369 min, P = 0.03). There was no significant difference in LN yield (22 vs 18 LNs, P = 0.34), EBL (100 vs 313 mL, P = 0.13), or LOS (2.75 vs 2.2 days, P = 0.36).

CONCLUSION: This initial selected case series of RA-RPLND shows that the procedure is safe, reproducible, and feasible for stage I-IIB NSGCT and RMS in the hands of experienced robotic surgeons. Larger studies are needed to confirm the diagnostic and therapeutic utility of this technique.

Original languageEnglish (US)
Pages (from-to)114-120
Number of pages7
JournalBJU International
Volume115
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Lymph Node Excision
Rhabdomyosarcoma
Operative Time
Length of Stay
Ejaculation
Lymph Nodes
Recurrence
Drug Therapy
Robotics
Neoplasms
Maintenance
Demography
Lung
Nonseminomatous germ cell tumor

Keywords

  • NSGCT
  • paratesticular rhabdomyosarcoma
  • RA-RPLND
  • retroperitoneal lymph node dissection
  • robotics
  • testicular cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Robot-assisted retroperitoneal lymph node dissection : technique and initial case series of 18 patients. / Cheney, Scott M.; Andrews, Paul E.; Leibovich, Bradley C.; Castle, Erik P.

In: BJU International, Vol. 115, No. 1, 01.01.2015, p. 114-120.

Research output: Contribution to journalArticle

Cheney, Scott M. ; Andrews, Paul E. ; Leibovich, Bradley C. ; Castle, Erik P. / Robot-assisted retroperitoneal lymph node dissection : technique and initial case series of 18 patients. In: BJU International. 2015 ; Vol. 115, No. 1. pp. 114-120.
@article{a87e2fc5fe794bc79868029734f9ec7b,
title = "Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients",
abstract = "OBJECTIVE: To evaluate outcomes of the first 18 patients treated with robot-assisted retroperitoneal lymph node dissection (RA-RPLND) for non-seminomatous germ cell tumours (NSGCT) and paratesticular rhabdomyosarcoma (RMS) at our institution.PATIENTS AND METHODS: Between March 2008 and May 2013, 17 patients underwent RA-RPLND for NSGCT and one for paratesticular RMS. Data were collected retrospectively on patient demographics, preoperative tumour characteristics, and perioperative outcomes including open conversion rate, lymph node (LN) yield, rate of positive LNs, operative time, estimated blood loss (EBL), and length of stay (LOS). Perioperative outcomes were compared between patients receiving primary RA-RPLND vs post-chemotherapy RA-RPLND. Medium-term outcomes of tumour recurrence rate and maintenance of antegrade ejaculation were recorded.RESULTS: RA-RPLND was completed robotically in 15 of 18 (83{\%}) patients. LNs were positive in eight of 18 patients (44{\%}). The mean LN yield was 22 LNs. For cases completed robotically, the mean operative time was 329 min, EBL was 103 mL, and LOS was 2.4 days. At a mean (range) follow-up of 22 (1-58) months, there were no retroperitoneal recurrences and two of 17 (12{\%}) patients with NSGCT had pulmonary recurrences. Antegrade ejaculation was maintained in 91{\%} of patients with a nerve-sparing approach. Patients receiving primary RA-RPLND had shorter operative times compared with those post-chemotherapy (311 vs 369 min, P = 0.03). There was no significant difference in LN yield (22 vs 18 LNs, P = 0.34), EBL (100 vs 313 mL, P = 0.13), or LOS (2.75 vs 2.2 days, P = 0.36).CONCLUSION: This initial selected case series of RA-RPLND shows that the procedure is safe, reproducible, and feasible for stage I-IIB NSGCT and RMS in the hands of experienced robotic surgeons. Larger studies are needed to confirm the diagnostic and therapeutic utility of this technique.",
keywords = "NSGCT, paratesticular rhabdomyosarcoma, RA-RPLND, retroperitoneal lymph node dissection, robotics, testicular cancer",
author = "Cheney, {Scott M.} and Andrews, {Paul E.} and Leibovich, {Bradley C.} and Castle, {Erik P}",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/bju.12804",
language = "English (US)",
volume = "115",
pages = "114--120",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Robot-assisted retroperitoneal lymph node dissection

T2 - technique and initial case series of 18 patients

AU - Cheney, Scott M.

AU - Andrews, Paul E.

AU - Leibovich, Bradley C.

AU - Castle, Erik P

PY - 2015/1/1

Y1 - 2015/1/1

N2 - OBJECTIVE: To evaluate outcomes of the first 18 patients treated with robot-assisted retroperitoneal lymph node dissection (RA-RPLND) for non-seminomatous germ cell tumours (NSGCT) and paratesticular rhabdomyosarcoma (RMS) at our institution.PATIENTS AND METHODS: Between March 2008 and May 2013, 17 patients underwent RA-RPLND for NSGCT and one for paratesticular RMS. Data were collected retrospectively on patient demographics, preoperative tumour characteristics, and perioperative outcomes including open conversion rate, lymph node (LN) yield, rate of positive LNs, operative time, estimated blood loss (EBL), and length of stay (LOS). Perioperative outcomes were compared between patients receiving primary RA-RPLND vs post-chemotherapy RA-RPLND. Medium-term outcomes of tumour recurrence rate and maintenance of antegrade ejaculation were recorded.RESULTS: RA-RPLND was completed robotically in 15 of 18 (83%) patients. LNs were positive in eight of 18 patients (44%). The mean LN yield was 22 LNs. For cases completed robotically, the mean operative time was 329 min, EBL was 103 mL, and LOS was 2.4 days. At a mean (range) follow-up of 22 (1-58) months, there were no retroperitoneal recurrences and two of 17 (12%) patients with NSGCT had pulmonary recurrences. Antegrade ejaculation was maintained in 91% of patients with a nerve-sparing approach. Patients receiving primary RA-RPLND had shorter operative times compared with those post-chemotherapy (311 vs 369 min, P = 0.03). There was no significant difference in LN yield (22 vs 18 LNs, P = 0.34), EBL (100 vs 313 mL, P = 0.13), or LOS (2.75 vs 2.2 days, P = 0.36).CONCLUSION: This initial selected case series of RA-RPLND shows that the procedure is safe, reproducible, and feasible for stage I-IIB NSGCT and RMS in the hands of experienced robotic surgeons. Larger studies are needed to confirm the diagnostic and therapeutic utility of this technique.

AB - OBJECTIVE: To evaluate outcomes of the first 18 patients treated with robot-assisted retroperitoneal lymph node dissection (RA-RPLND) for non-seminomatous germ cell tumours (NSGCT) and paratesticular rhabdomyosarcoma (RMS) at our institution.PATIENTS AND METHODS: Between March 2008 and May 2013, 17 patients underwent RA-RPLND for NSGCT and one for paratesticular RMS. Data were collected retrospectively on patient demographics, preoperative tumour characteristics, and perioperative outcomes including open conversion rate, lymph node (LN) yield, rate of positive LNs, operative time, estimated blood loss (EBL), and length of stay (LOS). Perioperative outcomes were compared between patients receiving primary RA-RPLND vs post-chemotherapy RA-RPLND. Medium-term outcomes of tumour recurrence rate and maintenance of antegrade ejaculation were recorded.RESULTS: RA-RPLND was completed robotically in 15 of 18 (83%) patients. LNs were positive in eight of 18 patients (44%). The mean LN yield was 22 LNs. For cases completed robotically, the mean operative time was 329 min, EBL was 103 mL, and LOS was 2.4 days. At a mean (range) follow-up of 22 (1-58) months, there were no retroperitoneal recurrences and two of 17 (12%) patients with NSGCT had pulmonary recurrences. Antegrade ejaculation was maintained in 91% of patients with a nerve-sparing approach. Patients receiving primary RA-RPLND had shorter operative times compared with those post-chemotherapy (311 vs 369 min, P = 0.03). There was no significant difference in LN yield (22 vs 18 LNs, P = 0.34), EBL (100 vs 313 mL, P = 0.13), or LOS (2.75 vs 2.2 days, P = 0.36).CONCLUSION: This initial selected case series of RA-RPLND shows that the procedure is safe, reproducible, and feasible for stage I-IIB NSGCT and RMS in the hands of experienced robotic surgeons. Larger studies are needed to confirm the diagnostic and therapeutic utility of this technique.

KW - NSGCT

KW - paratesticular rhabdomyosarcoma

KW - RA-RPLND

KW - retroperitoneal lymph node dissection

KW - robotics

KW - testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=84922412183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922412183&partnerID=8YFLogxK

U2 - 10.1111/bju.12804

DO - 10.1111/bju.12804

M3 - Article

C2 - 24825773

AN - SCOPUS:84922412183

VL - 115

SP - 114

EP - 120

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -